<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Niacin for primary and secondary prevention of cardiovascular events - Schandelmaier, S - 2017 | Cochrane Library</title> <meta content="Niacin for primary and secondary prevention of cardiovascular events - Schandelmaier, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009744.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Niacin for primary and secondary prevention of cardiovascular events - Schandelmaier, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009744.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009744.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Niacin for primary and secondary prevention of cardiovascular events" name="citation_title"/> <meta content="Stefan Schandelmaier" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Matthias Briel" name="citation_author"/> <meta content="University of Basel" name="citation_author_institution"/> <meta content="matthias.briel@usb.ch" name="citation_author_email"/> <meta content="Ramon Saccilotto" name="citation_author"/> <meta content="University of Basel" name="citation_author_institution"/> <meta content="Kelechi K Olu" name="citation_author"/> <meta content="University of Basel" name="citation_author_institution"/> <meta content="Armon Arpagaus" name="citation_author"/> <meta content="University of Basel" name="citation_author_institution"/> <meta content="Lars G Hemkens" name="citation_author"/> <meta content="University of Basel" name="citation_author_institution"/> <meta content="Alain J Nordmann" name="citation_author"/> <meta content="University of Basel" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009744.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009744.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009744.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009744.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Primary Prevention; *Secondary Prevention; Cardiovascular Diseases [mortality, *prevention &amp; control]; Myocardial Infarction [mortality, prevention &amp; control]; Niacin [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic [statistics &amp; numerical data]; Stroke [mortality, prevention &amp; control]; Vasodilator Agents [*administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009744.pub2&amp;doi=10.1002/14651858.CD009744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009744\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009744\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","fr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009744.pub2",title:"Niacin for primary and secondary prevention of cardiovascular events",firstPublishedDate:"Jun 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009744.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009744.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009744.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009744.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009744.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009744.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009744.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009744.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009744.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009744.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7241 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009744.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-sec-0077"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-sec-0069"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/appendices#CD009744-sec-0082"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/table_n/CD009744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/table_n/CD009744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Niacin for primary and secondary prevention of cardiovascular events</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#CD009744-cr-0002">Stefan Schandelmaier</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#CD009744-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Matthias Briel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#CD009744-cr-0004">Ramon Saccilotto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#CD009744-cr-0005">Kelechi K Olu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#CD009744-cr-0006">Armon Arpagaus</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#CD009744-cr-0007">Lars G Hemkens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information#CD009744-cr-0008">Alain J Nordmann</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information/en#CD009744-sec-0085">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009744.pub2">https://doi.org/10.1002/14651858.CD009744.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009744-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009744-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009744-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009744-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009744-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009744-abs-0001" lang="en"> <section id="CD009744-sec-0001"> <h3 class="title" id="CD009744-sec-0001">Background</h3> <p>Nicotinic acid (niacin) is known to decrease LDL‐cholesterol, and triglycerides, and increase HDL‐cholesterol levels. The evidence of benefits with niacin monotherapy or add‐on to statin‐based therapy is controversial. </p> </section> <section id="CD009744-sec-0002"> <h3 class="title" id="CD009744-sec-0002">Objectives</h3> <p>To assess the effectiveness of niacin therapy versus placebo, administered as monotherapy or add‐on to statin‐based therapy in people with or at risk of cardiovascular disease (CVD) in terms of mortality, CVD events, and side effects. </p> </section> <section id="CD009744-sec-0003"> <h3 class="title" id="CD009744-sec-0003">Search methods</h3> <p>Two reviewers independently and in duplicate screened records and potentially eligible full texts identified through electronic searches of CENTRAL, MEDLINE, Embase, Web of Science, two trial registries, and reference lists of relevant articles (latest search in August 2016). </p> </section> <section id="CD009744-sec-0004"> <h3 class="title" id="CD009744-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) that either compared niacin monotherapy to placebo/usual care or niacin in combination with other component versus other component alone. We considered RCTs that administered niacin for at least six months, reported a clinical outcome, and included adults with or without established CVD. </p> </section> <section id="CD009744-sec-0005"> <h3 class="title" id="CD009744-sec-0005">Data collection and analysis</h3> <p>Two reviewers used pre‐piloted forms to independently and in duplicate extract trials characteristics, risk of bias items, and outcomes data. Disagreements were resolved by consensus or third party arbitration. We conducted random‐effects meta‐analyses, sensitivity analyses based on risk of bias and different assumptions for missing data, and used meta‐regression analyses to investigate potential relationships between treatment effects and duration of treatment, proportion of participants with established coronary heart disease and proportion of participants receiving background statin therapy. We used GRADE to assess the quality of evidence. </p> </section> <section id="CD009744-sec-0006"> <h3 class="title" id="CD009744-sec-0006">Main results</h3> <p>We included 23 RCTs that were published between 1968 and 2015 and included 39,195 participants in total. The mean age ranged from 33 to 71 years. The median duration of treatment was 11.5 months, and the median dose of niacin was 2 g/day. The proportion of participants with prior myocardial infarction ranged from 0% (4 trials) to 100% (2 trials, median proportion 48%); the proportion of participants taking statin ranged from 0% (4 trials) to 100% (12 trials, median proportion 100%). </p> <p>Using available cases, niacin did not reduce overall mortality (risk ratio (RR) 1.05, 95% confidence interval (CI) 0.97 to 1.12; participants = 35,543; studies = 12; I<sup>2</sup> = 0%; high‐quality evidence), cardiovascular mortality (RR 1.02, 95% CI 0.93 to 1.12; participants = 32,966; studies = 5; I<sup>2</sup> = 0%; moderate‐quality evidence), non‐cardiovascular mortality (RR 1.12, 95% CI 0.98 to 1.28; participants = 32,966; studies = 5; I<sup>2</sup> = 0%; high‐quality evidence), the number of fatal or non‐fatal myocardial infarctions (RR 0.93, 95% CI 0.87 to 1.00; participants = 34,829; studies = 9; I<sup>2</sup> = 0%; moderate‐quality evidence), nor the number of fatal or non‐fatal strokes (RR 0.95, 95% CI 0.74 to 1.22; participants = 33,661; studies = 7; I<sup>2</sup> = 42%; low‐quality evidence). Participants randomised to niacin were more likely to discontinue treatment due to side effects than participants randomised to control group (RR 2.17, 95% CI 1.70 to 2.77; participants = 33,539; studies = 17; I<sup>2</sup> = 77%; moderate‐quality evidence). The results were robust to sensitivity analyses using different assumptions for missing data. </p> </section> <section id="CD009744-sec-0007"> <h3 class="title" id="CD009744-sec-0007">Authors' conclusions</h3> <p>Moderate‐ to high‐quality evidence suggests that niacin does not reduce mortality, cardiovascular mortality, non‐cardiovascular mortality, the number of fatal or non‐fatal myocardial infarctions, nor the number of fatal or non‐fatal strokes but is associated with side effects. Benefits from niacin therapy in the prevention of cardiovascular disease events are unlikely. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009744-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009744-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009744-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009744-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009744-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009744-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009744-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009744-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009744-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009744-abs-0004" lang="en"> <h3>Niacin for people with or without established cardiovascular disease</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effects of niacin for the prevention of death and cardiovascular disease. </p> <p><b>Background</b> </p> <p>Heart attack and stroke are the most common causes of death, illness, disability and reduced quality of life in industrialised countries. </p> <p>Niacin (nicotinic acid, vitamin B3) was considered a promising candidate to prevent cardiovascular disease because it is known to lower cholesterol in the blood, which is one of the main risk factors. Therefore, long‐term therapy with niacin was assumed to reduce the risk of heart attack, and stroke. We assessed whether clinical studies could show a benefit of taking niacin. </p> <p><b>Study characteristics</b> </p> <p>We found 23 studies including 39,195 participants that compared niacin to placebo. The evidence is current up to August 2016. The majority of included participants were on average 65 years old and had already experienced a myocardial infarction. The participants took niacin or placebo for a period of between six months and five years. Seventeen out of 23 studies were fully or partially funded by the drug manufacturer with a commercial interest in the results of the studies. </p> <p><b>Key results</b> </p> <p>Niacin did not reduce the number of deaths, heart attack or stroke. Many people (18%) had to stop taking niacin due to side effects. The results did not differ between participants who had or had not experienced a heart attack before taking niacin. The results did not differ between participants who were or were not taking a statin (another drug that prevents heart attack and stroke). The overall quality of evidence was moderate to high. </p> <p>In summary, we found no evidence of benefits from niacin therapy.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009744-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009744-sec-0077"></div> <h3 class="title" id="CD009744-sec-0078">Implications for practice</h3> <section id="CD009744-sec-0078"> <p>In summary, moderate‐ to high‐quality evidence suggests that niacin does not reduce mortality or cardiovascular events. Our confidence is increased by the fact that none of the outcomes showed a significant benefit, despite potential biases in favour of Niacin. Niacin cannot be recommended for primary or secondary prevention of cardiovascular events. </p> </section> <h3 class="title" id="CD009744-sec-0079">Implications for research</h3> <section id="CD009744-sec-0079"> <p>No further research is required to evaluate the role of niacin in the prevention of cardiovascular events. The body of evidence appears sufficient to conclude that niacin has no role in the primary or secondary prevention of cardiovascular events, not as mono nor as add‐on therapy. Considering the potential increase in overall mortality, as suggested by two large trials at low risk of bias, additional randomised controlled trials in similar populations would be unethical. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009744-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009744-sec-0022"></div> <div class="table" id="CD009744-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Niacin for primary and secondary prevention of cardiovascular events</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Niacin for primary and secondary prevention of cardiovascular events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with or at risk of cardiovascular disease<br/> <b>Setting:</b> secondary care and tertiary care<br/> <b>Intervention:</b> niacin monotherapy or add‐on<br/> <b>Comparison:</b> placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with niacin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall mortality<br/> (follow‐up: 0.5 years to 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.97 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35,543<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High‐quality evidence that niacin does not reduce overall mortality (CI excludes clinically important benefit) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (83 to 96) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> <p>(follow‐up: 1 year to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.93 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,966<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Moderate‐quality evidence that niacin does not reduce cardiovascular mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000<br/> (58 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐cardiovascular mortality</p> <p>(follow‐up: 1 year to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (0.98 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,966<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High‐quality evidence that niacin does not reduce non‐cardiovascular mortality (CI excludes clinically important benefit) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (24 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatal or non‐fatal myocardial infarction</p> <p>(follow up: 0.5 years to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.87 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,829<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Moderate‐quality evidence that niacin does not reduce the number of fatal and non‐fatal myocardial infarctions </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (83 to 95) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatal and non‐fatal stroke</p> <p>(follow‐up: 0.5 years to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.74 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33,661<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low‐quality evidence that niacin does not reduce the number of strokes</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (35 to 59) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Discontinuation of treatment due to side effects</p> <p>(follow‐up: 0.5 years to 4 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.17<br/> (1.70 to 2.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33,539<br/> (17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Moderate‐quality evidence that niacin does increase the number of participants discontinuing treatment due to side effects </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000<br/> (162 to 273) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval includes clinically relevant benefit and no benefit. We downgraded by one level due to imprecision.<br/> <sup>2</sup>High heterogeneity in point estimates. We downgraded by one level due to inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009744-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009744-sec-0023"></div> <section id="CD009744-sec-0024"> <h3 class="title" id="CD009744-sec-0024">Description of the condition</h3> <p>Cardiovascular disease (CVD) is the most common cause of death, illness, disability and reduced quality of life in industrialised countries (<a href="./references#CD009744-bbs2-0131" title="ThomT , HaaseN , RosamondW , HowardVJ , RumsfeldJ , ManolioT , et al. Heart disease and stroke statistics‐‐2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation2006;113(6):e85‐151. ">Thom 2006</a>). Mortality data for 2011 show that CVD accounted for one of three deaths in the USA (approximately 800,000) (<a href="./references#CD009744-bbs2-0122" title="American Heart Association Statistics Committee and Stroke Statistics Subcommittee, MozaffarianD , BenjaminEJ , GoAS , ArnettDK , BlahaMJ , CushmanM , et al. Heart disease and stroke statistics‐‐2015 update: a report from the American Heart Association. Circulation2015;131(24):e18‐e209. ">Mozaffarian 2015</a>). One of the major risk factors for CVD is elevated low‐density lipoprotein cholesterol (LDL‐C). In individuals with elevated LDL‐C, statins (HMG CoA reductase inhibitors) are considered to be the first choice of pharmacological therapy, since they reduce CVD events and total mortality independently of baseline LDL‐C levels (<a href="./references#CD009744-bbs2-0076" title="Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383‐9. ">4S 1994</a>; <a href="./references#CD009744-bbs2-0078" title="BaigentC , KeechA , KearneyP M , BlackwellL , BuckG , PollicinoC , et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366(9493):1267‐78. ">Baigent 2005</a>; <a href="./references#CD009744-bbs2-0097" title="GrahamI , AtarD , Borch‐JohnsenK , BoysenG , BurellG , et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. European Journal of Cardiovascular Prevention and Rehabilitation2007; Vol. 14 Suppl 2:S1‐113. ">Graham 2007</a>; <a href="./references#CD009744-bbs2-0100" title="Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet2002;360(9326):7‐22. ">HCSBG 2002</a>; <a href="./references#CD009744-bbs2-0105" title="HooperL , SummerbellCD , HigginsJPT , ThompsonRL , CappsNE , SmithGD , et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ (Clinical research ed.)2001;322(7289):757‐63. ">Hooper 2001</a>; <a href="./references#CD009744-bbs2-0114" title="LestraJA , KromhoutD , Van derSchouwYT , GrobbeeDE , BoshuizenHC , VanStaverenWA . Effect size estimates of lifestyle and dietary changes on all‐cause mortality in coronary artery disease patients: a systematic review. Circulation2005;112(6):924‐34. ">Lestra 2005</a>; <a href="./references#CD009744-bbs2-0120" title="MillsEJ , WuP , ChongG , GhementI , SinghS , AklEA , et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta‐analysis of 170 255 patients from 76 randomised trials. QJM : Monthly Journal of the Association of Physicians2010;104(2):109‐24. ">Mills 2010</a>). However, despite significant risk reduction with statin therapy, many cardiac events are not prevented. Moreover, some people are unable to tolerate or have contraindications to statin therapy. Therefore, further investigation of additional or alternative lipid‐lowering drug therapies is needed (<a href="./references#CD009744-bbs2-0087" title="CannonCP , GiuglianoRP , BlazingMA , HarringtonRA , PetersonJL , McCrary SiskC , et al. Rationale and design of IMPROVE‐IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal2008;156(5):826‐32. ">Cannon 2008</a>). </p> </section> <section id="CD009744-sec-0025"> <h3 class="title" id="CD009744-sec-0025">Description of the intervention</h3> <p>Nicotinic acid (niacin, vitamin B3) is a candidate to lower the remaining risk as it is known to decrease LDL‐C, triglycerides and lipoprotein (a). In addition, it is the most effective currently available drug to increase high‐density lipoprotein cholesterol (HDL‐C) levels by up to 35% (<a href="./references#CD009744-bbs2-0082" title="BirjmohunRS , HuttenBA , KasteleinJJ , StroesES . Efficacy and safety of high‐density lipoprotein cholesterol‐increasing compounds: a meta‐analysis of randomised controlled trials. Journal of the American College of Cardiology2005;45:185‐97. ">Birjmohun 2005</a>; <a href="./references#CD009744-bbs2-0115" title="McKenneyJ . New perspectives on the use of niacin in the treatment of lipid disorders. Archives of internal Medicine2004;164(7):697‐705. ">McKenney 2004</a>; <a href="./references#CD009744-bbs2-0127" title="SinghIM , ShishehborMH , AnsellBJ . High‐density lipoprotein as a therapeutic target: a systematic review. JAMA2007;298(7):786‐98. ">Singh 2007</a>). Common side effects of niacin therapy include skin flushing (up to 71%), headache (8%), pruritus (6%) and gastrointestinal symptoms (10%) (<a href="./references#CD009744-bbs2-0079" title="BallantyneCM , DavidsonMH , McKenneyJM , KellerLH , BajorunasDR , KarasRH . Comparison of the efficacy and safety of a combination tablet of niacin extended‐release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high‐dose) study. Journal of Clinical Lipidology2008;2(2):79‐90. ">Ballantyne 2008a</a>; <a href="./references#CD009744-bbs2-0080" title="BallantyneCM , DavidsonMH , McKenneyJ , KellerLH , BajorunasDR , Karas RichardH . Comparison of the safety and efficacy of a combination tablet of niacin ER and simvastatin vs simvastatin monotherapy in patients with increased non‐HDL cholesterol (from the SEACOAST I study). The American Journal of Cardiology2008;101(10):1428‐36. ">Ballantyne 2008b</a>; <a href="./references#CD009744-bbs2-0107" title="InsullW , BasileJN , VoAN , JiangP , ThakkarR , PadleyRJ . Efficacy and safety of combination therapy with niacin extended‐release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. Journal of Clinical Lipidology2009;3(2):109‐18. ">Insull 2009</a>; <a href="./references#CD009744-bbs2-0111" title="KarasRH , KashyapM , KnoppR , KellerL , BajorunasD , DavidsonM . Long‐term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia. American Journal of Cardiovascular Drugs2008;8(2):69‐81. ">Karas 2008</a>; <a href="./references#CD009744-bbs2-0136" title="ZhaoX‐Q , MorseJS , DowdyAA , HeiseN , DeAngelisD , FrohlichJ , et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high‐density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). The American Journal of Cardiology2004;93(3):307‐12. ">Zhao 2004</a>). Skin flushing often leads to discontinuation of niacin treatment, although it is a tachyphylactic phenomenon, that is, once the body compensates, it is most likely that the frequency and intensity of such episodes will decrease within days or weeks and may even go away completely. Therefore, strategies to reduce flushing were developed, including modified release preparations, administration of aspirin, and formulation with laropiprant. Glucose intolerance with or without overt diabetes is another potential side effect of niacin therapy and may require adjustment of antihyperglycaemic therapy (<a href="./references#CD009744-bbs2-0098" title="GrundySM , VegaGL , McGovernME , TullochBR , KendallDM , Fitz‐PatrickD , et al. Efficacy, safety, and tolerability of once‐daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Archives of Internal Medicine2002;162(14):1568‐76. ">Grundy 2002</a>). </p> </section> <section id="CD009744-sec-0026"> <h3 class="title" id="CD009744-sec-0026">How the intervention might work</h3> <p>A meta‐analysis published in 2006 and including 23 studies found that CVD event rates are reduced by nearly 1% for each 1% reduction in LDL‐C and by at least 1% for each 1% increase in HDL‐C, regardless of LDL‐C reduction (<a href="./references#CD009744-bbs2-0084" title="BrownBG , StukovskyKH , ZhaoX . Simultaneous low‐density lipoprotein‐C lowering and high‐density lipoprotein‐C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta‐analysis of 23 randomised lipid trials. Current Opinion in Lipidology2006;17(6):631‐6. ">Brown 2006</a>). These findings imply a significant benefit of HDL‐C‐raising therapy independent of LDL‐C reduction. However, a systematic review and meta‐regression analysis including 108 studies found no additional effect of raised HDL‐C levels on fatal or non‐fatal myocardial infarction or overall mortality when the analysis was adjusted for changes in LDL‐C levels (<a href="./references#CD009744-bbs2-0083" title="BrielM , Ferreira‐GonzalezI , YouJJ , KaranicolasPJ , AklEA , WuP , et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta‐regression analysis. BMJ (Clinical research ed.)2009;338:b92. ">Briel 2009</a>). A more recent meta‐regression analysis also raised doubt as to the proposed relationship between HDL‐C and risk of cardiac events (<a href="./references#CD009744-bbs2-0106" title="Hourcade‐PotelleretF , LaporteS , LehnertV , DelmarP , BenghoziR , TorrianiU , et al. Clinical benefit from pharmacological elevation of high‐density lipoprotein cholesterol: meta‐regression analysis. Heart2015;101:847‐53. ">Hourcade‐Potelleret 2015</a>). </p> <p>Decision analytic computer models have been used to estimate the economic value in terms of costs per life years gained for niacin therapy in addition to existing lipid‐lowering therapy with statins. With incremental cost‐effectiveness ratios (ICER) between EUR 10,000 and EUR 20,000, add‐on niacin therapy was judged to be cost‐effective (<a href="./references#CD009744-bbs2-0119" title="MichailovGV , DaviesGM , KrobotKJ . Cost‐effectiveness of extended‐release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. The European Journal of Health Economics2011;13(3):365‐74. ">Michailov 2011</a>; <a href="./references#CD009744-bbs2-0125" title="RozeS , FerrieresJ , BruckertE , VanGanseE , ChapmanM J , LiensD , et al. Cost‐effectiveness of raising HDL cholesterol by adding prolonged‐release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective. International Journal of Clinical Practice2007;61(11):1805‐11. ">Roze 2007</a>). However, these models rely on the assumption of an additional outcome benefit due to raised HDL‐C levels, which is yet to be determined. Nevertheless, the cost of niacin treatment is generally considered to be low (<a href="./references#CD009744-bbs2-0118" title="MeyersCD , CarrMC , ParkS , BrunzellJD . Varying cost and free nicotinic acid content in over‐the‐counter niacin preparations for dyslipidemia. Annals of Internal Medicine2003;139(12):996‐1002. ">Meyers 2003</a>). </p> </section> <section id="CD009744-sec-0027"> <h3 class="title" id="CD009744-sec-0027">Why it is important to do this review</h3> <p>The evidence of CVD benefits with niacin therapy is controversial. Several randomised trials have investigated the efficacy and safety of niacin alone or in combination with other lipid‐modifying drugs, focusing mostly on surrogate end points like changes in lipid profiles or carotid intima‐media thickness as primary outcomes (e.g. <a href="./references#CD009744-bbs2-0079" title="BallantyneCM , DavidsonMH , McKenneyJM , KellerLH , BajorunasDR , KarasRH . Comparison of the efficacy and safety of a combination tablet of niacin extended‐release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high‐dose) study. Journal of Clinical Lipidology2008;2(2):79‐90. ">Ballantyne 2008a</a>; <a href="./references#CD009744-bbs2-0086" title="CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8(6):1245‐55. ">Canner 1986</a>; <a href="./references#CD009744-bbs2-0109" title="The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231(4):360‐81. ">JAMA 1975</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0121" title="MooreA , Phan BinhAP , ChallenderC , WilliamsonJ , MarcovinaS , ZhaoX‐Q . Effects of adding extended‐release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. Journal of Clinical Lipidology2007;1(6):620‐5. ">Moore 2007</a>; <a href="./references#CD009744-bbs2-0129" title="TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110(23):3512‐7. ">Taylor 2004</a>; <a href="./references#CD009744-bbs2-0130" title="TaylorAJ , VillinesTC , StanekEJ , DevinePJ , GriffenL , MillerM , et al. Extended‐release niacin or ezetimibe and carotid intima‐media thickness. The New England Journal of Medicine2009;361(22):2113‐22. ">Taylor 2009</a>; <a href="./references#CD009744-bbs2-0133" title="VaccariCS , NagamiaS , ThoenesM , OguchiA , HammoudR , KhanBV . Efficacy of controlled‐release niacin in treatment of metabolic syndrome: correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation. Journal of Clinical Lipidology2007;1(6):605‐13. ">Vaccari 2007</a>). Several previous meta‐analyses investigated the effects of lipid‐modifying drugs and included niacin RCTs. However, these meta‐analyses were either not based on systematic reviews (<a href="./references#CD009744-bbs2-0093" title="GoldbergAC . A meta‐analysis of randomised controlled studies on the effects of extended‐release niacin in women. American Journal of Cardiology2004;94:121‐4. ">Goldberg 2004</a>, <a href="./references#CD009744-bbs2-0099" title="GuytonJR , SimmonsPD . Flushing and other dermatologic adverse events associated with extended‐release niacin therapy. Journal of Clinical Lipidolology2009;3:101‐8. ">Guyton 2009a</a>, <a href="./references#CD009744-bbs2-0081" title="BaysHE , ShahA , LinJ , SiskCM , DongQ , MaccubbinD . Consistency of extended‐release niacin/laropiprant effects on Lp(a), ApoB, non‐HDL‐C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups. American Journal of Cardiovascular Drugs2012;12:197‐206. ">Bays 2012a</a>, <a href="./references#CD009744-bbs2-0116" title="McKenneyJ , BaysH , KorenM , BallantyneCM , PaoliniJF , MitchelY , et al. Safety of extended‐release niacin/laropiprant in patients with dyslipidemia. Journal of Clinal Lipidology2010;4:105‐112 e1. ">McKenney 2010</a>, <a href="./references#CD009744-bbs2-0117" title="McKenneyJ , BaysH , GleimG , MitchelY , KuznetsovaO , SapreA , et al. Safety and tolerability of extended‐release niacin‐laropiprant: pooled analyses for 11,310 patients in 12 controlled clinical trials. Journal of Clinal Lipidology2015;9:313‐25. ">McKenney 2015</a>) or they included niacin combination therapy (i.e. niacin plus another agent) or active control groups (e.g. niacin versus other lipid‐modifying drugs) where it is impossible to discern any potentially incremental effects of niacin (<a href="./references#CD009744-bbs2-0082" title="BirjmohunRS , HuttenBA , KasteleinJJ , StroesES . Efficacy and safety of high‐density lipoprotein cholesterol‐increasing compounds: a meta‐analysis of randomised controlled trials. Journal of the American College of Cardiology2005;45:185‐97. ">Birjmohun 2005</a>; <a href="./references#CD009744-bbs2-0085" title="BruckertE , LabreucheJ , AmarencoP . Meta‐analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis2010;210(2):353‐61. ">Bruckert 2010</a>; <a href="./references#CD009744-bbs2-0088" title="CharlandSL , MaloneDC . Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current Medical Research Opinion2010;26:365‐75. ">Charland 2010</a>; <a href="./references#CD009744-bbs2-0090" title="DuggalJK , SinghM , AttriN , SinghPP , AhmedN , PahwaS , et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(2):158‐66. ">Duggal 2010</a>; <a href="./references#CD009744-bbs2-0094" title="GoldieC , TaylorAJ , NguyenP , McCoyC , ZhaoXQ , PreissD . Niacin therapy and the risk of new‐onset diabetes: a meta‐analysis of randomised controlled trials. Heart2015 [Epub ahead of print]:1. ">Goldie 2015</a>; <a href="./references#CD009744-bbs2-0095" title="GouldAL , DaviesGM , AlemaoE , YinDD , CookJR . Cholesterol reduction yields clinical benefits: meta‐analysis including recent trials. Clinal Therapeutics2007;29:778‐94. ">Gould 2007</a>; <a href="./references#CD009744-bbs2-0112" title="KeeneD , PriceC , Shun‐ShinMJ , FrancisDP . Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta‐analysis of randomised controlled trials including 117,411 patients. BMJ2014;349:g4379. ">Keene 2014</a>; <a href="./references#CD009744-bbs2-0134" title="VerdoiaM , SchafferA , SuryapranataH , DeLucaG . Effects of HDL‐modifiers on cardiovascular outcomes: a meta‐analysis of randomised trials. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25:9‐23. ">Verdoia 2015</a>). We identified only one previous systematic review and meta‐analysis that addressed explicitly the incremental effect of niacin on patient‐relevant outcomes: <a href="./references#CD009744-bbs2-0108" title="IpCK , JinDM , GaoJJ , MengZ , MengJ , TanZ , et al. Effects of add‐on lipid‐modifying therapy on top of background statin treatment on major cardiovascular events: a meta‐analysis of randomised controlled trials. International Journal of Cardiology2015;191:138‐48. ">Ip 2015</a> assessed the effect of add‐on lipid‐modifying therapy on top of background statin treatment on major cardiovascular events. They included various comparisons but presented the subgroup of three RCTs that investigated the effect of niacin as add‐on therapy (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>). None of the summary effects on clinical outcomes were significant. The risk ratio (RR) for all‐cause mortality was 1.10 (95% confidence interval (CI) 1.00 to 1.20, I<sup>2</sup> = 0%), the RR for major cardiovascular events was 1.03 (95% CI 0.85 to 1.25, I<sup>2</sup> = 48%), the RR for death from coronary heart disease was 1.07 (95% CI 0.94 to 1.21, I<sup>2</sup> = 0%), the RR for myocardial infarction was 1.00 (95% CI 0.83 to 1.20, I<sup>2</sup> = 29%), and the RR for stroke was 1.52 (CI 0.57 to 4.06. I<sup>2</sup> = 11%) in favour of the placebo group. However, the meta‐analysis was limited to high risk patients taking background statin therapy and failed to discuss methodological limitations of included trials. The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults recommends considering re‐emphasising adherence to lifestyle changes and to statin therapy before adding a non‐statin drug (<a href="./references#CD009744-bbs2-0077" title="American College of Cardiology/American Heart Association Task Force on Practice Guidelines, StoneNJ , RobinsonJG , LichtensteinAH , Bairey MerzCN , BlumCB , EckelRH , et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014;66(129 (25 Suppl 2)):S1‐45. ">ACC/AHA guideline 2013</a>). The expert panel could not find any data supporting the routine use of non‐statin drugs combined with statin therapy to reduce cardiovascular events. In addition, no randomised controlled trials (RCTs) evaluating the effect of non‐statin drugs on cardiovascular outcomes in statin‐intolerant individuals were found. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009744-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009744-sec-0028"></div> <p>To assess the effectiveness of niacin therapy versus placebo administered as monotherapy or add‐on to statin‐based therapy in people with or at risk of cardiovascular (CVD) disease in terms of mortality, CDV events, and side effects. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009744-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009744-sec-0029"></div> <section id="CD009744-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009744-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included RCTs (published and unpublished) that documented an outcome of interest and had a treatment time (and thus follow‐up) of at least six months. </p> </section> <section id="CD009744-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults 18 years or older with or without established CVD disease.</p> </section> <section id="CD009744-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD009744-list-0001"> <li> <p>Combination therapy including niacin plus other lipid‐modifying drug(s) versus other lipid‐modifying drug(s) alone for at least six months </p> </li> <li> <p>Niacin monotherapy versus placebo or usual care for at least six months</p> </li> </ul> </p> </section> <section id="CD009744-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD009744-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009744-list-0002"> <li> <p>Overall mortality</p> </li> </ul> </p> </section> <section id="CD009744-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009744-list-0003"> <li> <p>Fatal myocardial infarction (including sudden death)</p> </li> <li> <p>Cardiovascular mortality (any death from cardiac or vascular cause)</p> </li> <li> <p>Non‐cardiovascular mortality</p> </li> <li> <p>Non‐fatal myocardial infarction</p> </li> <li> <p>Fatal or non‐fatal myocardial infarction</p> </li> <li> <p>Fatal or non‐fatal stroke</p> </li> <li> <p>Revascularisation procedures (bypass grafts, angioplasty)</p> </li> <li> <p>Patient‐perceived quality of life (only measured using validated scales)</p> </li> <li> <p>Side effects, that is, skin flushing, pruritus, rash, headache, gastrointestinal symptoms, new onset of diabetes </p> </li> <li> <p>Discontinuation of treatment due to side effects</p> </li> <li> <p>Information on costs</p> </li> </ul> </p> </section> </section> </section> <section id="CD009744-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009744-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 23 August 2016: Cochrane Central Register of Controlled Trials (CENTRAL, 2016, Issue 7) in the Cochrane Library, 'Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE' (Ovid, 1946 to 23 August 2016), 'Embase Classic and Embase' (Ovid, 1947 to 2016 August 22), and Web of Science (Thomson Reuters, 1970 to 23 August 2016). </p> <p>When searching MEDLINE and Embase we used the Cochrane sensitivity‐maximising filter for RCTs (<a href="./references#CD009744-bbs2-0113" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. ">Lefebvre 2011</a>) and an adaptation of it for Web of Science. The search strategies used can be found in <a href="./appendices#CD009744-sec-0083">Appendix 1</a>. No date or language restrictions were imposed. </p> </section> <section id="CD009744-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We further screened reference lists of included studies, published editorials, and previous systematic reviews or meta‐analysis reviews on the topic (<a href="./references#CD009744-bbs2-0081" title="BaysHE , ShahA , LinJ , SiskCM , DongQ , MaccubbinD . Consistency of extended‐release niacin/laropiprant effects on Lp(a), ApoB, non‐HDL‐C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups. American Journal of Cardiovascular Drugs2012;12:197‐206. ">Bays 2012a</a>; <a href="./references#CD009744-bbs2-0082" title="BirjmohunRS , HuttenBA , KasteleinJJ , StroesES . Efficacy and safety of high‐density lipoprotein cholesterol‐increasing compounds: a meta‐analysis of randomised controlled trials. Journal of the American College of Cardiology2005;45:185‐97. ">Birjmohun 2005</a>; <a href="./references#CD009744-bbs2-0085" title="BruckertE , LabreucheJ , AmarencoP . Meta‐analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis2010;210(2):353‐61. ">Bruckert 2010</a>; <a href="./references#CD009744-bbs2-0088" title="CharlandSL , MaloneDC . Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current Medical Research Opinion2010;26:365‐75. ">Charland 2010</a>; <a href="./references#CD009744-bbs2-0090" title="DuggalJK , SinghM , AttriN , SinghPP , AhmedN , PahwaS , et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. Journal of Cardiovascular Pharmacology and Therapeutics2010;15(2):158‐66. ">Duggal 2010</a>; <a href="./references#CD009744-bbs2-0093" title="GoldbergAC . A meta‐analysis of randomised controlled studies on the effects of extended‐release niacin in women. American Journal of Cardiology2004;94:121‐4. ">Goldberg 2004</a>; <a href="./references#CD009744-bbs2-0095" title="GouldAL , DaviesGM , AlemaoE , YinDD , CookJR . Cholesterol reduction yields clinical benefits: meta‐analysis including recent trials. Clinal Therapeutics2007;29:778‐94. ">Gould 2007</a>; <a href="./references#CD009744-bbs2-0099" title="GuytonJR , SimmonsPD . Flushing and other dermatologic adverse events associated with extended‐release niacin therapy. Journal of Clinical Lipidolology2009;3:101‐8. ">Guyton 2009a</a>; <a href="./references#CD009744-bbs2-0106" title="Hourcade‐PotelleretF , LaporteS , LehnertV , DelmarP , BenghoziR , TorrianiU , et al. Clinical benefit from pharmacological elevation of high‐density lipoprotein cholesterol: meta‐regression analysis. Heart2015;101:847‐53. ">Hourcade‐Potelleret 2015</a>; <a href="./references#CD009744-bbs2-0108" title="IpCK , JinDM , GaoJJ , MengZ , MengJ , TanZ , et al. Effects of add‐on lipid‐modifying therapy on top of background statin treatment on major cardiovascular events: a meta‐analysis of randomised controlled trials. International Journal of Cardiology2015;191:138‐48. ">Ip 2015</a>; <a href="./references#CD009744-bbs2-0112" title="KeeneD , PriceC , Shun‐ShinMJ , FrancisDP . Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta‐analysis of randomised controlled trials including 117,411 patients. BMJ2014;349:g4379. ">Keene 2014</a>; <a href="./references#CD009744-bbs2-0116" title="McKenneyJ , BaysH , KorenM , BallantyneCM , PaoliniJF , MitchelY , et al. Safety of extended‐release niacin/laropiprant in patients with dyslipidemia. Journal of Clinal Lipidology2010;4:105‐112 e1. ">McKenney 2010</a>; <a href="./references#CD009744-bbs2-0117" title="McKenneyJ , BaysH , GleimG , MitchelY , KuznetsovaO , SapreA , et al. Safety and tolerability of extended‐release niacin‐laropiprant: pooled analyses for 11,310 patients in 12 controlled clinical trials. Journal of Clinal Lipidology2015;9:313‐25. ">McKenney 2015</a>; <a href="./references#CD009744-bbs2-0124" title="RobinsonJ G , WangS , SmithB J , JacobsonT A . Meta‐analysis of the relationship between non‐high‐density lipoprotein cholesterol reduction and coronary heart disease risk. Journal of the American College of Cardiology2009;53:316‐22. ">Robinson 2009a</a>; <a href="./references#CD009744-bbs2-0127" title="SinghIM , ShishehborMH , AnsellBJ . High‐density lipoprotein as a therapeutic target: a systematic review. JAMA2007;298(7):786‐98. ">Singh 2007</a>; <a href="./references#CD009744-bbs2-0134" title="VerdoiaM , SchafferA , SuryapranataH , DeLucaG . Effects of HDL‐modifiers on cardiovascular outcomes: a meta‐analysis of randomised trials. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25:9‐23. ">Verdoia 2015</a>). </p> <p>In addition, we searched clinical trials registries in August 2016, (<a href="http://www.clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> and <a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>) for additional eligible studies and additional publications of included RCTs. We searched registries using synonyms for niacin ("niacin", "nicotinic", "vitamin B"). </p> </section> </section> <section id="CD009744-sec-0040"> <h3 class="title" id="CD009744-sec-0040">Data collection and analysis</h3> <section id="CD009744-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Investigators, working in teams of two (SS, AN), independently reviewed potentially eligible titles and abstracts. If either reviewer believed the study to be eligible, we obtained the full report. After obtaining full reports of the candidate studies (either in full peer‐reviewed publication or press article) the two reviewers independently assessed eligibility from full‐text papers. Discrepancies were resolved by reviewers’ consensus or, if needed, third party arbitration. </p> </section> <section id="CD009744-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two reviewers (SS and AN) used pre‐piloted forms to independently extract all relevant data on baseline characteristics of trials, participant populations, and outcomes. Any disagreements between reviewers were resolved by consensus. </p> </section> <section id="CD009744-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Working in teams of two, we independently assessed the quality of each included trial with respect to random sequence generation, concealment of treatment allocation, blinding of participants, caregivers, or assessors of clinical outcomes, completeness of follow‐up (<a href="./references#CD009744-bbs2-0110" title="JüniP , WitschiA , BlochR , EggerM . The hazards of scoring the quality of clinical trials for meta‐analysis. JAMA1999;282(11):1054‐60. ">Jüni 1999</a>), and selective reporting of outcomes (<a href="./references#CD009744-bbs2-0104" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). The results are presented as risk of bias tables as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009744-bbs2-0104" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Possible disagreement was resolved by consensus or third party arbitration if needed. We explored the influence of risk of bias on the primary outcome in a sensitivity analysis excluding RCTs with high or unclear risk of bias. </p> </section> <section id="CD009744-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>Ratio of risk for harmful events (risk ratio) and accompanying 95% confidence intervals.</p> </section> <section id="CD009744-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We checked for outcome reporting bias by comparing reported outcomes to outcomes mentioned in corresponding trial protocols (provided they were published prospectively) or trial registry records (provided the trial was registered prospectively). We investigated the presence of publication bias by means of funnel plots (<a href="./references#CD009744-bbs2-0091" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical research ed.)1997;315(7109):629‐34. ">Egger 1997</a>; <a href="./references#CD009744-bbs2-0128" title="SterneJA , EggerM , SmithGD . Systematic reviews in health care: investigating and dealing with publication and other biases in meta‐analysis. BMJ (Clinical research ed.)2001;323(7304):101‐5. ">Sterne 2001</a>). </p> </section> <section id="CD009744-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We used random‐effects model meta‐analyses to calculate a weighted average of risk ratios across studies for all outcomes. We did not assume that all studies measure the same underlying true effect (that is, fixed‐effect across studies) since we included primary and secondary prevention studies, and studies with and without background statin treatment. If a study reported more than one eligible comparison, we pooled the intervention arms and the control arms of the eligible comparisons. Whenever possible, we analysed participants as randomised irrespective of adherence to treatment. However, some studies excluded protocol violators from the follow‐up or reported analysis. In that case, we also excluded them from our primary analysis, which was based on available cases. We considered available case analysis as our primary analysis because the underlying assumption is that missing data occurred at random. The commonly reported approach of using all randomised participants as a denominator for risks implicitly assumes no event for missing data which is less realistic than missing at random. We conducted all analyses using Review Manager 5 (RevMan 5) (<a href="./references#CD009744-bbs2-0123" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and Stata 13 (<a href="http://www.stata.com/" target="_blank">stata.com</a>). </p> <p>In our analyses we made the following assumptions:</p> <p> <ul id="CD009744-list-0004"> <li> <p>If the denominator for available cases was not explicitly reported, we calculated the denominator by subtracting lost to follow‐up from all randomised participants. For outcomes for which lost to follow‐up was not reported, we assumed the available case denominator as reported or calculated for other outcomes. If the denominator differed by outcomes, we used the smallest. </p> </li> <li> <p>If a binary outcome was reported, both as a component of a composite endpoint (first occurrence) and as an independent outcome, we preferred the independent outcome in order to prevent bias due to competing risks. </p> </li> <li> <p>If myocardial infarction was not explicitly defined as fatal or non‐fatal, we counted the events as 'fatal or non‐fatal myocardial infarction' only. We used the same strategy for undefined stroke. </p> </li> <li> <p>If a specific side effect was reported both as 'discontinuation of treatment due to side effect' and 'experience of side effect', we preferred the latter in order to avoid assessment bias. </p> </li> <li> <p>If a specific side effect was only reported in combination with another side effect but not as an individual component (e.g. 'flushing or pruritus') we used the combined outcome in the meta‐analysis of the individual component that occurred more frequently in other studies that reported both components. For example, if a study reported the outcome 'flushing or pruritus' we used 'flushing' in the meta‐analysis because flushing occurred more frequently in other studies that reported both components separately. </p> </li> <li> <p>If several subcategories of an outcome (e.g. 'diarrhoea' as subcategory of 'gastrointestinal side effects') were reported but were not mutually exclusive, we assumed the outcome with the most events to represent the superordinate category. For instance, in a study that reported the outcomes 'diarrhoea' and 'vomiting', and 'diarrhoea' had more events than 'vomiting', we considered 'diarrhoea' to represent 'gastrointestinal side effects'. </p> </li> <li> <p>If a study reported that a participant was withdrawn from the study, but did not explicitly state whether the participant was withdrawn from the intervention (non‐adherent) or from the follow‐up (missing outcome data), we assumed withdrawal from follow‐up. </p> </li> </ul> </p> </section> <section id="CD009744-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We tested for heterogeneity with Cochrane’s Q‐test (<a href="./references#CD009744-bbs2-0089" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>; <a href="./references#CD009744-bbs2-0101" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>) and used I<sup>2</sup> (<a href="./references#CD009744-bbs2-0102" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ (Clinical research ed.)2003;327(7414):557‐60. ">Higgins 2003</a>) to measure inconsistency of treatment effects across primary and secondary outcomes. We conducted inverse variance‐weighted meta‐regression analysis (<a href="./references#CD009744-bbs2-0132" title="ThompsonSG , SharpSJ . Explaining heterogeneity in meta‐analysis: a comparison of methods. Statistics in Medicine1999;18(20):2693‐708. ">Thompson 1999</a>) to investigate any association between the outcomes and duration of niacin therapy, proportion of participants with established coronary heart disease, and proportion of participants receiving background statin therapy. </p> </section> <section id="CD009744-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses for all outcomes by assuming three different relationships between outcomes of missing and observed participants (<a href="./references#CD009744-bbs2-0103" title="HigginsJP , WhiteIR , WoodAM . Imputation methods for missing outcome data in meta‐analysis of clinical trials. Clinical Trials2008;5:225‐39. ">Higgins 2008</a>; command "metamiss" in Stata, <a href="#CD009744-tbl-0002">Table 1</a> (<a href="http://www.stata.com/" target="_blank">stata.com</a>)). Therefore, we specified the informative missingness odds ratio (IMOR = odds of event in missing data/odds of event in observed data) and specified a distribution of the assumed relationship of the standard deviation (logIMOR = 0.5) to account for the uncertainty of this assumption. For the first sensitivity analysis, we assumed missingness at random (IMOR 1.0 in each arm) that results in similar point estimates for the individual trials but may change the summary estimate by down‐weighting studies with high proportions of missing data. In the second sensitivity analysis, we assumed a lower IMOR of 0.5 in the niacin arms and a higher IMOR of 2.0 in the control arms, thereby shifting the estimate in favour of niacin treatment. In a third sensitivity analysis, we assumed an IMOR of 2.0 in the intervention arms and an IMOR of 0.5 in the niacin arms thereby shifting the estimate in favour of the control treatment. We did draw forest plots given the minimal differences and large number of sensitivity analyses. For the primary outcome, we also conducted a sensitivity analysis restricting the analysis to trials with low risk of bias. </p> <div class="table" id="CD009744-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis assuming different relationship between the outcomes from observed and missing participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Available case analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> IMOR 1.0, 1.0*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> IMOR 0.5, 2.0*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> IMOR 2.0, 0.5*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> I<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> I<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> I<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> I<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.97 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.97 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.96 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.98 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.93 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.93 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.92 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.94 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.98 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.98 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.97 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (1.00 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.87 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.87 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.86 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.87 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.91 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.91 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.90 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.92 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.77 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.77 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.76 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.77 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.74 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.74 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.73 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.75 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.68 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.68 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.66 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.69 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16 (1.70 to 2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.15 (1.68 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.96 (1.55 to 2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.35 (1.82 to 3.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.69 (4.15 to 14.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.66 (4.11 to 14.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.68 (3.54 to 12.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.61 (4.67 to 15.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.16 (1.96 to 5.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.14 (1.93 to 5.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.74 (1.80 to 4.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.69 (2.13 to 6.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.15 (2.62 to 10.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.21 (2.68 to 10.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.23 (1.94 to 9.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.48 (3.78 to 11.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (1.37 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (1.36 to 2.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (1.23 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.88 (1.48 to 2.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.86 to 2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (0.83 to 2.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.64 to 2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 (1.05 to 2.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>IMOR</b> : informative missingness odds ratio; <b>RR</b>: risk ratio </p> <p>Sensitivity analysis for random‐effects meta‐analysis assuming different relationship between the outcomes from observed and missing participants and accounting for the uncertainty introduced by the proportion of missing data and assumed relationship (informative missingness odds ratio, IMOR = odds of event in missing data/odds of event in observed data, SD(logIMOR) = 0.5). We used the “metamiss”‐command in Stata (version 13) (<a href="http://www.stata.com/" target="_blank">stata.com</a>). </p> <p>*The two numbers represent the assumed IMORs for the niacin and the control arm, respectively: 1.0, 1.0: missing at random; 0.5, 2.0: assumption favours niacin, 2.0, 0.5: assumption favours control. </p> <p>We could not conduct sensitivity analysis for the outcome 'new onset diabetes' because the proportion of missing data was not reported. </p> </div> </div> <section id="CD009744-sec-0049"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table using the following outcomes: overall mortality, cardiovascular mortality, non‐cardiovascular mortality, fatal or non‐fatal myocardial infarction, fatal or non‐fatal stroke, and discontinuation of treatment due to side effects. We used the five GRADE considerations (risk of bias, inconsistency, imprecision, indirectness and publication bias) to assess the quality of a body of evidence. We used methods and recommendations described in Section 8.5 (<a href="./references#CD009744-bbs2-0104" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>) and Chapter 12 (<a href="./references#CD009744-bbs2-0126" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> using <a href="./references#CD009744-bbs2-0096" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed September 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a> software. We used footnotes to justify all decisions to downgrade the quality of evidence. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009744-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009744-sec-0050"></div> <section id="CD009744-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD009744-sec-0052"> <h4 class="title">Results of the search</h4> <p>The search yielded 5631 unique records. We screened the full texts of 382 potentially eligible articles and finally included 23 RCTs (reported in 75 references) in our analysis (<a href="#CD009744-fig-0001">Figure 1</a>; <a href="./references#CD009744-sec-0091" title="">Characteristics of included studies</a>). We excluded 307 articles including 65 RCTs involving niacin treatment that did not fulfil our eligibility criteria (<a href="#CD009744-sec-0059">Excluded studies</a>). </p> <div class="figure" id="CD009744-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD009744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD009744-sec-0053"> <h4 class="title">Included studies</h4> <section id="CD009744-sec-0054"> <h5 class="title">Methodology</h5> <p>We included 23 RCTs that were published between 1968 and 2015. In total, we included 39,195 participants. The median duration of treatment was 11.5 months. Of the 23 RCTs, there was one prospectively published protocol (<a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>) and five retrospectively published protocols (after end of recruitment) (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>; <a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>); 12 (52%) RCTs were registered in a clinical trials registry (all <a href="https://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>). Pharmaceutical companies were mentioned as the only funding source in ten RCTs (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>; <a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a>; <a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>) and provided partial funding in another seven RCTs (<a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a>; <a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a>; <a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a>; <a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>; <a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a>); four RCTs were explicitly not industry funded (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a>; <a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>) and funding was not disclosed in two RCTs (<a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a>; <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a>). </p> </section> <section id="CD009744-sec-0055"> <h5 class="title">Populations</h5> <p>Mean age ranged from 33 to 71 years across individual trials. Most trials included more men than women, two trials included as many women as men and only one trial (<a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>) included more women than men. In two RCTs, all participants had experienced a prior myocardial infarction (<a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a>; <a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a>) (secondary prevention trials). Four trials explicitly excluded people with prior myocardial infarction (<a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>; <a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a>; <a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a>) (primary prevention trials). In the remaining trials (mixed prevention trials), the proportion of individuals with prior myocardial infarction was in the range of 9% to 89% (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>; <a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a>; <a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>; <a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a>; <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a>) or was not reported in four trials (<a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a>; <a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>). </p> <p>Of the 23 included RCT populations, 16 (70%) received therapy with statin (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>; <a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a>; <a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a>; <a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>; <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a>). The proportions of individuals receiving statin therapy ranged from 67% to 100%. Statin therapy was part of the randomised interventions in eight RCTs, part of inclusion criteria in three RCTs, and part of allowed background therapy in five RCTs. The proportion of individuals receiving statins was 0% in four RCTs and not reported in three RCTs. </p> <p>Most trials recruited participants in North America (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>; <a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a>; <a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a>; <a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>; <a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a>), followed by Europe (<a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a>; <a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a>), Asia (<a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a>; <a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a>; <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a>), or recruited world‐wide (<a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>). Most studies did not report on the healthcare setting; four included participants in tertiary care (<a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a>), one in secondary care (<a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>), and three from mixed healthcare settings (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>; <a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>). </p> </section> <section id="CD009744-sec-0056"> <h5 class="title">Interventions</h5> <p>The included trials administered a median dose of niacin of 2 g/day (range 0.5 g/day to 4.0 g/day) and the duration of treatment ranged between six months and six years. Nineteen trials applied one or more methods to reduce skin flushing due to niacin intake: Ten trials used an extended‐release formula (<a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>; <a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>; <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a>), four trials combined niacin with laropiprant (<a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>), ten trials gave aspirin prior to intake of niacin (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>; <a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a>) and nine trials recommended intake at bedtime to reduce flushing, some together with a snack (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a>). Four trials (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>; <a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>) applied a placebo that contained a minimal dose of niacin, enough to trigger skin flushes but with no effect on lipid levels, in order to prevent unblinding due to flushing. </p> <p><a href="#CD009744-tbl-0003">Table 2</a> provides an overview of the change in lipid parameters associated with niacin therapy for each included RCT. Niacin increased the concentration of HDL‐C and decreased the concentration of triglycerides in all studies that reported these data. Niacin decreased the concentrations of LDL‐C and total cholesterol in most studies. </p> <div class="table" id="CD009744-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Lipid data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Niacin dose g/day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up in months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cholesterol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LDL‐cholesterol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HDL‐cholesterol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Triglycerides</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Baseline mean, <br/>(treatment effect: difference between niacin and control group in mean change from baseline) in mg/dL </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 (‐4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 (‐6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (+11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176 (‐34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 (‐3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (+10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 (‐21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136 (+1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (+2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (+3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158 (‐19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 (+3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (+8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (‐12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (+3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (‐6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237 (‐6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 (‐16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249 (‐20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 (‐31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 (‐48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (+8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 (NA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241 (‐4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (+11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 (‐30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (‐11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (+5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157 (‐5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211 (‐7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (+5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306 (‐25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (‐5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (‐10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 (‐33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 (‐10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (+24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197 (‐23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157 (+1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (‐15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (+22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (‐7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 (NA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218 (+4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (+5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154 (‐29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223 (‐20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (+22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 (‐57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 (‐33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 (+21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (‐15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178 (‐15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (‐22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (+8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (‐21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 (‐4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (+8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 (‐26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 (‐8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 (‐13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (+1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 (‐25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 (NA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242 (‐34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>NA</b>: not available </p> </div> </div> </section> <section id="CD009744-sec-0057"> <h5 class="title">Comparisons</h5> <p>Of the 23 RCTs, 14 had a placebo for niacin in the control group (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>; <a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a>; <a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a>; <a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>; <a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>; <a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a>). The remaining nine RCTs administered standard treatment without a specific placebo for niacin (<a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a>; <a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a>; <a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a>; <a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a>; <a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a>; <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a>). </p> </section> <section id="CD009744-sec-0058"> <h5 class="title">Outcomes</h5> <p>Ten trials specified a serum lipid parameter as their primary outcome (<a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a>; <a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a>; <a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>; <a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a>; <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a>; <a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a>), seven trials an angiographic outcome (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>; <a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a>), two trials a composite of cardiovascular events (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>), one trial feasibility (<a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a>), and another trial overall mortality (<a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a>). Two trials did not specify a primary outcome (<a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a>; <a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a>). </p> <p>Of the 23 RCTs, 12 (52%) reported the outcome overall mortality, the primary outcome of the present systematic review. Of these, five specified overall mortality explicitly as an outcome (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>; <a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a>; <a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a>) while the remaining seven studies reported overall mortality under safety/adverse events (<a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a>; <a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>; <a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a>; <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a>). </p> <p>None of the included studies reported information about quality of life or costs.</p> </section> </section> <section id="CD009744-sec-0059"> <h4 class="title">Excluded studies</h4> <p>Overall, we excluded 65 RCT reports that involved niacin treatment but did not report a comparison of interest (36 RCT reports), had a follow‐up shorter than six months (21 RCT reports), or reported no ocutome of interest (8 RCT reports) (see <a href="./references#CD009744-sec-0092" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD009744-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD009744-fig-0002">Figure 2</a> and <a href="#CD009744-fig-0002">Figure 2</a> provide an overview of the risk of bias in individual studies. </p> <div class="figure" id="CD009744-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD009744-sec-0061"> <h4 class="title">Allocation</h4> <p>Eleven trials reported a method to generate the random sequence (low risk of bias), 11 trials did not report the method of random sequence generation (unclear risk of bias), and one trial used quasi randomisation (high risk of bias) (<a href="#CD009744-fig-0002">Figure 2</a>). </p> <p>Eight trials reported an adequate method to conceal allocation (low risk of bias), 13 trials reported no method (unclear risk of bias), and two trials did clearly not conceal allocation (high risk of bias) (<a href="#CD009744-fig-0002">Figure 2</a>).. </p> </section> <section id="CD009744-sec-0062"> <h4 class="title">Blinding</h4> <p>Sixteen trials were reported as double‐blind (low risk of performance bias), five as open‐label and one as single‐blind (high risk of performance bias), and the blinding status of participants and study personnel remained unclear in one trial (unclear risk of performance bias) (<a href="#CD009744-fig-0002">Figure 2</a>). </p> <p>Outcome assessment was blinded in five trials (low risk of detection bias), not mentioned in 12 trials (unclear risk of detection bias), and unblinded in six trials (high risk of detection bias) (<a href="#CD009744-fig-0002">Figure 2</a>). </p> </section> <section id="CD009744-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>We judged the risk of attrition bias as high in 11 trials (proportion of missing data &gt; 10%, or ratio events/missing &lt; 1), unclear in two studies, and low in the remaining 10 studies (<a href="#CD009744-fig-0002">Figure 2</a>). The median proportion of missing data in the 12 trials that reported overall mortality was 25% in the intervention arms and 19% in the control arm (<a href="#CD009744-tbl-0004">Table 3</a>). None of the included trials mentioned a sensitivity analysis for missing outcome data with respect to the clinical outcomes. </p> <div class="table" id="CD009744-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number randomised, complete, missing, and events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Niacin group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Complete</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Complete</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign=""> <p><a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>341</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal and non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign=""> <p><a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>709</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>633</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>535</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>386</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>839</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>311</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>385</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New onset diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign=""> <p><a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>694</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>431</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>411</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>499</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>897</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>732</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New onset diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>491</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New onset diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009744-sec-0064"> <h4 class="title">Selective reporting</h4> <p>We systematically compared planned and reported outcomes in ten studies that provided a prospectively published protocol (<a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>) or prospectively published registry record (<a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>; <a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a>; <a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a>; <a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a>; <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>; <a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a>; <a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a>; <a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a>; <a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>). Of these, we judged the risk of outcome reporting bias as high for one study that failed to report pre‐specified cardiovascular events (<a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a>). The trials <a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a>, <a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>, and <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a> reported all pre‐specified outcomes and were therefore judged as being at low risk of reporting bias. We judged the risk of reporting bias in the remaining five trials with a prospective protocol as unclear because the clinical outcomes that we extracted (e.g. death or flushing) were reported as side effects but not pre‐specified as separate outcomes. The risk of reporting bias was unclear for the 13 trials without published protocol or registry record (<a href="#CD009744-fig-0002">Figure 2</a>). </p> </section> <section id="CD009744-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>We considered <a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a> at high risk of bias because the reported information was insufficient to rate any item of the risk of bias tool. In addition, treatment groups were considerably unbalanced with respect to cardiovascular risk factors, prior myocardial infarction (control: 36%, intervention 10%) and diabetes (control: 16%, intervention 54%) which raises doubts whether the method of randomisation was appropriate. </p> <p>One trial was stopped early for futility (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a>). It has been argued that stopping early for futility bears a potential risk for underestimation of potential treatment effects (<a href="./references#CD009744-bbs2-0135" title="WalterSD , HanH , BrielM , GuyattG . Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility. Statistics in Medicine2017;36(9):1506‐18. ">Walter 2017</a>). However, we considered a relevant bias extremely unlikely given the conservative stopping rules and point estimates consistently excluding any benefits. </p> </section> </section> <section id="CD009744-sec-0066"> <h3 class="title" id="CD009744-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD009744-tbl-0001"><b>Summary of findings for the main comparison</b> Niacin for primary and secondary prevention of cardiovascular events</a> </p> <section id="CD009744-sec-0067"> <h4 class="title">Primary outcome</h4> <p>Twelve RCTs reported the primary outcome of overall mortality. Using available cases, we found high‐quality evidence that niacin did not reduce overall mortality (RR 1.05, 95% CI 0.97 to 1.12; participants = 35,543; studies = 12; I<sup>2</sup> = 0%; <a href="./references#CD009744-fig-0007" title="">Analysis 1.1</a>). The sensitivity analyses using relatively extreme assumptions for imputation of missing data did not change the primary outcome (<a href="#CD009744-tbl-0002">Table 1</a>). When we considered only the two trials at low risk of bias (<a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a> and <a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>) as a sensitivity analysis, the pooled results suggested that niacin may increase overall mortality (RR 1.10, 95% CI 1.00 to 1.20; participants = 28,840; studies = 2; I<sup>2</sup> = 0% <a href="./references#CD009744-fig-0008" title="">Analysis 1.2</a>). </p> <p>Meta‐regression analyses did not suggest a significant effect modification by duration of treatment (P = 0.15, <a href="#CD009744-fig-0003">Figure 3</a>), proportion of participants with established coronary heart disease (P = 0.19, <a href="#CD009744-fig-0004">Figure 4</a>), or proportion of participants receiving background statin therapy (P = 0.15, <a href="#CD009744-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD009744-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Meta‐regression by duration of treatment using the 'matreg' command in Stata version 13 (stata.com) (Number of observations: 12, P = 0.15)" data-id="CD009744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Meta‐regression by duration of treatment using the 'matreg' command in Stata version 13 (<a href="http://www.stata.com/" target="_blank">stata.com</a>) (Number of observations: 12, P = 0.15) </p> </div> </div> </div> <div class="figure" id="CD009744-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Meta‐regression by proportion of participants with prior myocardial infarction using the 'matreg' command in Stata version 13 (stata.com) (Number of observations:8, P = 0.19)" data-id="CD009744-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Meta‐regression by proportion of participants with prior myocardial infarction using the 'matreg' command in Stata version 13 (<a href="http://www.stata.com/" target="_blank">stata.com</a>) (Number of observations:8, P = 0.19) </p> </div> </div> </div> <div class="figure" id="CD009744-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Meta‐regression by proportion of participants receiving background statin therapy using the 'matreg' command in Stata version 13 (stata.com) (Number of observations: 10, P = 0.15)" data-id="CD009744-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Meta‐regression by proportion of participants receiving background statin therapy using the 'matreg' command in Stata version 13 (<a href="http://www.stata.com/" target="_blank">stata.com</a>) (Number of observations: 10, P = 0.15) </p> </div> </div> </div> </section> <section id="CD009744-sec-0068"> <h4 class="title">Secondary outcomes</h4> <p>The effect of niacin was not significant in any cardiovascular outcome.</p> <p>Using available cases, niacin did not reduce:</p> <p> <ul id="CD009744-list-0005"> <li> <p>the number of fatal myocardial infarctions (RR 1.01, 95% CI 0.91 to 1.11; participants = 33,336; studies = 6; I<sup>2</sup> = 0%, moderate‐quality evidence, downgraded due to imprecision, <a href="./references#CD009744-fig-0009" title="">Analysis 1.3</a>); </p> </li> <li> <p>cardiovascular mortality (RR 1.02, 95% CI 0.93 to 1.12; participants = 32,966; studies = 5; I<sup>2</sup> = 0%, moderate‐quality evidence, downgraded due to imprecision, <a href="./references#CD009744-fig-0010" title="">Analysis 1.4</a>); </p> </li> <li> <p>non‐cardiovascular mortality (RR 1.12, 95% CI 0.98 to 1.28; participants = 32,966; studies = 5; I<sup>2</sup> = 0%; high‐quality evidence, <a href="./references#CD009744-fig-0011" title="">Analysis 1.5</a>); </p> </li> <li> <p>the number of non‐fatal myocardial infarctions (RR 0.91, 95% CI 0.77 to 1.07; participants = 33,164; studies = 4; I<sup>2</sup> = 53%, low‐quality evidence, downgraded due to imprecision and inconsistency, <a href="./references#CD009744-fig-0012" title="">Analysis 1.6</a>); </p> </li> <li> <p>the number of fatal or non‐fatal myocardial infarctions (RR 0.93, 95% CI 0.87 to 1.00; participants = 34,829; studies = 9; I<sup>2</sup> = 0%, moderate‐quality evidence, downgraded due to imprecision, <a href="./references#CD009744-fig-0013" title="">Analysis 1.7</a>); </p> </li> <li> <p>the number of fatal or non‐fatal strokes (RR 0.95, 95% CI 0.74 to 1.22; participants = 33,661; studies = 7; I<sup>2</sup> = 42%, low‐quality evidence, downgraded due to imprecision and inconsistency, <a href="./references#CD009744-fig-0014" title="">Analysis 1.8</a>); nor </p> </li> <li> <p>the number of revascularisation procedures (RR 0.85, 95% CI 0.68 to 1.06; participants = 33,130; studies = 8; I<sup>2</sup> = 45%, low‐quality evidence, downgraded due to imprecision and inconsistency, <a href="./references#CD009744-fig-0015" title="">Analysis 1.9</a>). </p> </li> </ul> </p> <p>Using available cases, niacin increased the number of side effects, specifically:</p> <p> <ul id="CD009744-list-0006"> <li> <p>flushing (RR 7.69, 95% CI 4.14 to 14.28; participants = 11,038; studies = 15; I<sup>2</sup> = 91%, moderate‐quality evidence, downgraded due to inconsistency, <a href="./references#CD009744-fig-0016" title="">Analysis 1.10</a>); </p> </li> <li> <p>pruritus (RR 5.26, 95% CI 2.68 to 10.32; participants = 5800; studies = 6; I<sup>2</sup> = 66%, moderate‐quality evidence, downgraded due to inconsistency, <a href="./references#CD009744-fig-0017" title="">Analysis 1.11</a>); </p> </li> <li> <p>rash (RR 3.15, 95% CI 1.94 to 5.13; participants = 31,485; studies = 9; I<sup>2</sup> = 52%, moderate‐quality evidence, downgraded due to inconsistency, <a href="./references#CD009744-fig-0018" title="">Analysis 1.12</a>); </p> </li> <li> <p>headache (RR 1.40, 95% CI 0.86 to 2.28; participants = 300; studies = 3; I<sup>2</sup> = 0%, moderate‐quality evidence, downgraded due to imprecision, <a href="./references#CD009744-fig-0019" title="">Analysis 1.13</a>); </p> </li> <li> <p>gastrointestinal symptoms (RR 1.69, 95% CI 1.37 to 2.07; participants = 35,353; studies = 12; I<sup>2</sup> = 60%, moderate‐quality evidence, downgraded due to inconsistency, <a href="./references#CD009744-fig-0020" title="">Analysis 1.14</a>); and </p> </li> <li> <p>discontinuation of treatment due to side effects (RR 2.17, 95% CI 1.70 to 2.77; participants = 33,539; studies = 17; I<sup>2</sup> = 77%, moderate‐quality evidence, downgraded due to inconsistency, <a href="./references#CD009744-fig-0021" title="">Analysis 1.15</a>). </p> </li> </ul> </p> <p>The statistical heterogeneity (I<sup>2</sup>) was high for the outcomes flushing, pruritus, rash, gastrointestinal symptoms, and discontinuation of treatment due to side effects, and we could not explain the heterogeneity by dose, pharmacological measures to prevent side effects, use of run‐in or enrichment period, or risk of bias. Therefore, we downgraded our judgement of the quality of evidence due to statistical inconsistency. However, the consistent directions of effects and the generally large effect sizes leave no doubt that niacin does substantially increases the number of side effects. Although the exact size of the estimate is compromised by the inconsistency, the clinical implication is clear and pooling seems appropriate. </p> <p>Sensitivity analyses using different assumptions for missing data did not affect the conclusion for any secondary outcome (<a href="#CD009744-tbl-0002">Table 1</a>. We did not draw forest plots given the minimal differences and large number of sensitivity analyses. </p> <p>For the outcome of new onset of diabetes, none of the three included studies reported available case analysis. Instead, we considered all randomised participants (which assumes no events for missing participants). The pooled results suggested that Niacin increased the number of participants developing diabetes (RR 1.32, 95% CI 1.16 to 1.51; participants = 27,982; studies = 3; I<sup>2</sup> = 0%, high‐quality evidence, <a href="./references#CD009744-fig-0022" title="">Analysis 1.16</a>). We did not downgrade due to risk of attrition bias because the proportion of missing data was as low as 1% in the dominating trial (<a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>). Therefore, we considered the risk of bias to be low for the body of evidence. </p> <p>None of the studies reported information about quality of life or costs.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009744-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009744-sec-0069"></div> <section id="CD009744-sec-0070"> <h3 class="title" id="CD009744-sec-0070">Summary of main results</h3> <p>We found high‐quality evidence that niacin does not reduce the risk for overall mortality. A sensitivity analysis limited to the two RCTs at low risk of bias (28,840 participants), suggested that niacin may even increase the number of deaths. We found no significant effect modification by duration of treatment, prior myocardial infarction, or background statin therapy. </p> <p>We found moderate‐ to high‐quality evidence that niacin does not reduce any other cardiovascular outcomes such as cardiovascular mortality, non‐cardiovascular mortality, fatal myocardial infarctions, non‐fatal myocardial infarction, or fatal or non‐fatal myocardial infarction. Low‐quality evidence suggested that niacin does not reduce the number of fatal or non‐fatal strokes, or revascularisation procedures. </p> <p>We found moderate‐quality evidence that niacin does substantially increase the number of participants discontinuing treatment due to side effects and the number of selected side effects such as flushing, pruritus, rash, and gastrointestinal symptoms, but also the serious side effect of new onset diabetes. </p> </section> <section id="CD009744-sec-0071"> <h3 class="title" id="CD009744-sec-0071">Overall completeness and applicability of evidence</h3> <section id="CD009744-sec-0072"> <h4 class="title">Completeness</h4> <p>We extensively searched the literature and carefully screened reference lists of relevant articles. Although we are confident that we did not miss any relevant study, potential selective outcome reporting might affect our results. First, the proportion of trials contributing to the meta‐analysis for our primary outcome (overall mortality) was below 50% when we also consider the six excluded RTCs that failed to report any clinically relevant outcome (<a href="./references#CD009744-bbs2-0092" title="FurukawaTA , WatanabeN , OmoriIM , MontoriV M , GuyattGH . Association between unreported outcomes and effect size estimates in Cochrane meta‐analyses. JAMA2007;297:468‐70. ">Furukawa 2007</a>). In addition, the funnel plot of the primary outcome was asymmetrical and suggested that positive studies were more likely to be published (<a href="#CD009744-fig-0006">Figure 6</a>). Since positive study bias would overestimate beneficial effects of niacin, it is unlikely that missing studies may have biased our conclusion that niacin is not beneficial. </p> <div class="figure" id="CD009744-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 niacin over placebo, maximum follow‐up, available case analysis, outcome: 1.1 overall mortality" data-id="CD009744-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 niacin over placebo, maximum follow‐up, available case analysis, outcome: 1.1 overall mortality </p> </div> </div> </div> </section> <section id="CD009744-sec-0073"> <h4 class="title">Applicability</h4> <p>Low heterogeneity despite considerable variety in populations suggests that the absence of beneficial effects of niacin treatment on mortality and cardiovascular outcomes are widely applicable. The generalisability is further supported by the fact that the meta‐regression analyses did not show any significant association between effect estimate and duration of treatment, secondary or primary prevention, or background statin therapy. Although there was high statistical heterogeneity in side effects and discontinuation of treatment due to side effects, the clinical interpretation that niacin does substantially increase the number of side effects was consistent across studies and can be generalised. </p> </section> </section> <section id="CD009744-sec-0074"> <h3 class="title" id="CD009744-sec-0074">Quality of the evidence</h3> <p>The meta‐analyses were largely driven by one large trial at low risk of bias (<a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>). Therefore, although we considered most trials to be at high risk of bias, mainly due to missing data, we did not downgrade any outcome for risk of bias. The results were robust in a sensitivity analysis where we made relatively extreme assumptions for missing outcome data (<a href="#CD009744-tbl-0002">Table 1</a>). Moreover, other potential sources of bias such as performance bias due to open‐label medication or detection bias through unblinded outcome assessment were unlikely to affect our conclusions because the anticipated direction of these biases would favour niacin. Following the same logic, we did not downgrade for potential publications bias; the funnel plot for the main outcome was skewed in favour of positive studies (<a href="#CD009744-fig-0006">Figure 6</a>). </p> <p>We downgraded our certainty in effects due to imprecision when the confidence interval of the overall effect included both no effect and potential benefit. When the confidence interval excluded benefit but included no effect and potential harm, we did not downgrade. The rationale for the latter approach is that the distinction between no effect and harm is irrelevant for clinical decision‐making; the clinical interest lies in potential benefits of niacin. </p> <p>We downgraded two outcomes for inconsistency. Overall, the quality of evidence ranged between high and moderate; quality was low only for the stroke outcome. </p> </section> <section id="CD009744-sec-0075"> <h3 class="title" id="CD009744-sec-0075">Potential biases in the review process</h3> <p>We screened all potentially relevant abstracts and full texts in duplicate and extracted included studies in duplicate. A potential limitation is that we did not systematically search the grey literature and did not systematically contact authors of identified studies for additional unpublished data. However, given the lack of significant benefits of niacin therapy, the large number of participants in our meta‐analysis, and the low heterogeneity, only a large trial demonstrating a clear benefit could affect the conclusions. It is unlikely that we missed such a trial. </p> <p>We made a number of (conservative) assumptions when outcome details were not clearly reported, as specified under data synthesis. A survey of investigators would have been optimal. However, the reporting quality of the main trial (<a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a>) was high and the potential risk of bias introduced by these assumptions therefore minimal. </p> </section> <section id="CD009744-sec-0076"> <h3 class="title" id="CD009744-sec-0076">Agreements and disagreements with other studies or reviews</h3> <p>Our conclusions are in line with the conclusions of related meta‐analyses. <a href="./references#CD009744-bbs2-0108" title="IpCK , JinDM , GaoJJ , MengZ , MengJ , TanZ , et al. Effects of add‐on lipid‐modifying therapy on top of background statin treatment on major cardiovascular events: a meta‐analysis of randomised controlled trials. International Journal of Cardiology2015;191:138‐48. ">Ip 2015</a> reported a potentially harmful effect of niacin on overall mortality when niacin is administered on top of background statin treatment in high‐risk participants (RR 1.10, 95% CI 1.00 to 1.20, I<sup>2</sup> = 0%), which is identical to our estimate based on the two trials at low risk of bias. Regarding new onset of diabetes, a recent meta‐analysis (<a href="./references#CD009744-bbs2-0094" title="GoldieC , TaylorAJ , NguyenP , McCoyC , ZhaoXQ , PreissD . Niacin therapy and the risk of new‐onset diabetes: a meta‐analysis of randomised controlled trials. Heart2015 [Epub ahead of print]:1. ">Goldie 2015</a>) found that "Niacin therapy was associated with an increase of new onset diabetes of RR 1.34 (95% CIs 1.21 to 1.49)". Although Goldie et at included RCTs evaluating niacin combination therapy, the estimate was very similar to our estimate (RR 1.32, 95% CI 1.16 to 1.51, I<sup>2</sup> = 0%). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009744-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD009744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Meta‐regression by duration of treatment using the 'matreg' command in Stata version 13 (stata.com) (Number of observations: 12, P = 0.15)" data-id="CD009744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Meta‐regression by duration of treatment using the 'matreg' command in Stata version 13 (<a href="http://www.stata.com/" target="_blank">stata.com</a>) (Number of observations: 12, P = 0.15) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Meta‐regression by proportion of participants with prior myocardial infarction using the 'matreg' command in Stata version 13 (stata.com) (Number of observations:8, P = 0.19)" data-id="CD009744-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Meta‐regression by proportion of participants with prior myocardial infarction using the 'matreg' command in Stata version 13 (<a href="http://www.stata.com/" target="_blank">stata.com</a>) (Number of observations:8, P = 0.19) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Meta‐regression by proportion of participants receiving background statin therapy using the 'matreg' command in Stata version 13 (stata.com) (Number of observations: 10, P = 0.15)" data-id="CD009744-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Meta‐regression by proportion of participants receiving background statin therapy using the 'matreg' command in Stata version 13 (<a href="http://www.stata.com/" target="_blank">stata.com</a>) (Number of observations: 10, P = 0.15) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 niacin over placebo, maximum follow‐up, available case analysis, outcome: 1.1 overall mortality" data-id="CD009744-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 niacin over placebo, maximum follow‐up, available case analysis, outcome: 1.1 overall mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 1 Overall mortality." data-id="CD009744-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 1 Overall mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 2 Overall mortality, sensitivity analysis with stratification by risk of bias trials only." data-id="CD009744-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 2 Overall mortality, sensitivity analysis with stratification by risk of bias trials only. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 3 Fatal myocardial infarction." data-id="CD009744-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 3 Fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 4 Cardiovascular mortality." data-id="CD009744-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 4 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 5 Non‐cardiovascular mortality." data-id="CD009744-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 5 Non‐cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 6 Non‐fatal myocardial infarction." data-id="CD009744-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 6 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 7 Fatal or non‐fatal myocardial infarction." data-id="CD009744-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 7 Fatal or non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 8 Fatal and non‐fatal stroke." data-id="CD009744-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 8 Fatal and non‐fatal stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 9 Revascularisation procedures." data-id="CD009744-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 9 Revascularisation procedures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 10 Flushing." data-id="CD009744-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 10 Flushing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 11 Pruritus." data-id="CD009744-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 11 Pruritus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 12 Rash." data-id="CD009744-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 12 Rash. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 13 Headache." data-id="CD009744-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 13 Headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 14 Gastrointestinal symptoms." data-id="CD009744-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 14 Gastrointestinal symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 15 Discontinuation of treatment due to side effects." data-id="CD009744-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 15 Discontinuation of treatment due to side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009744-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/urn:x-wiley:14651858:media:CD009744:CD009744-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_t/tCD009744-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 16 New onset diabetes)." data-id="CD009744-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Niacin versus control, maximum follow‐up, available case analysis, Outcome 16 New onset diabetes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/media/CDSR/CD009744/image_n/nCD009744-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009744-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Niacin for primary and secondary prevention of cardiovascular events</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Niacin for primary and secondary prevention of cardiovascular events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with or at risk of cardiovascular disease<br/> <b>Setting:</b> secondary care and tertiary care<br/> <b>Intervention:</b> niacin monotherapy or add‐on<br/> <b>Comparison:</b> placebo or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with niacin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall mortality<br/> (follow‐up: 0.5 years to 5 years) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.97 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35,543<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High‐quality evidence that niacin does not reduce overall mortality (CI excludes clinically important benefit) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (83 to 96) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> <p>(follow‐up: 1 year to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/> (0.93 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,966<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Moderate‐quality evidence that niacin does not reduce cardiovascular mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000<br/> (58 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Non‐cardiovascular mortality</p> <p>(follow‐up: 1 year to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/> (0.98 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,966<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High‐quality evidence that niacin does not reduce non‐cardiovascular mortality (CI excludes clinically important benefit) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (24 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatal or non‐fatal myocardial infarction</p> <p>(follow up: 0.5 years to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.87 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,829<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Moderate‐quality evidence that niacin does not reduce the number of fatal and non‐fatal myocardial infarctions </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (83 to 95) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Fatal and non‐fatal stroke</p> <p>(follow‐up: 0.5 years to 5 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.74 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33,661<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low‐quality evidence that niacin does not reduce the number of strokes</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (35 to 59) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Discontinuation of treatment due to side effects</p> <p>(follow‐up: 0.5 years to 4 years)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.17<br/> (1.70 to 2.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33,539<br/> (17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Moderate‐quality evidence that niacin does increase the number of participants discontinuing treatment due to side effects </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000<br/> (162 to 273) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval includes clinically relevant benefit and no benefit. We downgraded by one level due to imprecision.<br/> <sup>2</sup>High heterogeneity in point estimates. We downgraded by one level due to inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Niacin for primary and secondary prevention of cardiovascular events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009744-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis assuming different relationship between the outcomes from observed and missing participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Available case analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> IMOR 1.0, 1.0*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> IMOR 0.5, 2.0*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> IMOR 2.0, 0.5*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> I<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> I<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> I<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> I<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.97 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05 (0.97 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.96 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.98 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.93 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.93 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.92 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.94 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.98 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.98 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.97 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (1.00 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.87 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.87 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.86 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 (0.87 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.91 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.91 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.90 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02 (0.92 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.77 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.77 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.76 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 (0.77 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.74 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.74 to 1.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.73 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.75 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.68 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.68 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.66 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 (0.69 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16 (1.70 to 2.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.15 (1.68 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.96 (1.55 to 2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.35 (1.82 to 3.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.69 (4.15 to 14.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.66 (4.11 to 14.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.68 (3.54 to 12.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.61 (4.67 to 15.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.16 (1.96 to 5.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.14 (1.93 to 5.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.74 (1.80 to 4.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.69 (2.13 to 6.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.15 (2.62 to 10.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.21 (2.68 to 10.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.23 (1.94 to 9.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.48 (3.78 to 11.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (1.37 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69 (1.36 to 2.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 (1.23 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.88 (1.48 to 2.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 (0.86 to 2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 (0.83 to 2.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 (0.64 to 2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 (1.05 to 2.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>IMOR</b> : informative missingness odds ratio; <b>RR</b>: risk ratio </p> <p>Sensitivity analysis for random‐effects meta‐analysis assuming different relationship between the outcomes from observed and missing participants and accounting for the uncertainty introduced by the proportion of missing data and assumed relationship (informative missingness odds ratio, IMOR = odds of event in missing data/odds of event in observed data, SD(logIMOR) = 0.5). We used the “metamiss”‐command in Stata (version 13) (<a href="http://www.stata.com/" target="_blank">stata.com</a>). </p> <p>*The two numbers represent the assumed IMORs for the niacin and the control arm, respectively: 1.0, 1.0: missing at random; 0.5, 2.0: assumption favours niacin, 2.0, 0.5: assumption favours control. </p> <p>We could not conduct sensitivity analysis for the outcome 'new onset diabetes' because the proportion of missing data was not reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis assuming different relationship between the outcomes from observed and missing participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009744-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Lipid data</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Niacin dose g/day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up in months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cholesterol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LDL‐cholesterol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HDL‐cholesterol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Triglycerides</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Baseline mean, <br/>(treatment effect: difference between niacin and control group in mean change from baseline) in mg/dL </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 (‐4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138 (‐6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (+11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176 (‐34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 (‐3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (+10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165 (‐21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136 (+1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (+2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (+3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158 (‐19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 (+3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (+8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 (‐12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (+3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377 (‐6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237 (‐6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 (‐16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249 (‐20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 (‐31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 (‐48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (+8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191 (NA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241 (‐4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (+11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 (‐30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112 (‐11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (+5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157 (‐5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211 (‐7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (+5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306 (‐25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 (‐5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (‐10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (+6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 (‐33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 (‐10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (+24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>197 (‐23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157 (+1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 (‐15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (+22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (‐7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 (NA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218 (+4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (+5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154 (‐29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192 (‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223 (‐20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (+22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 (‐57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 (‐33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 (+21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (‐15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178 (‐15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (‐22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (+8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141 (‐21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 (‐4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 (+8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 (‐26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 (‐8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 (‐13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (+1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 (‐25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 (NA)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242 (‐34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA (NA)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>NA</b>: not available </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Lipid data</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009744-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number randomised, complete, missing, and events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Niacin group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Control group</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Complete</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Complete</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missing</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009744-bbs2-0001" title="ChesneyCM , ElamMB , HerdJA , DavisKB , GargR , HunninghakeD , et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). American Heart Journal2000;140:631‐6. EganDA , GargR , WiltTJ , PettingerMB , DavisKB , CrouseJ , et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. American Journal of Cardiology1999;83:569‐75. ElamMB , HunninghakeDB , DavisKB , GargR , JohnsonC , EganD , et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomised trial. Arterial Disease Multiple Intervention Trial. JAMA2000;284:1263‐70. GargR , ElamMB , CrouseJR3rd , DavisKB , KennedyJW , EganD , et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. American Heart Journal2000;140:792‐803. GargR , MalinowM , PettingerM , UpsonB , HunninghakeD . Niacin treatment increases plasma homocyst(e)ine levels. American Heart Journal1999;138:1082‐7. ">ADMIT 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign=""> <p><a href="./references#CD009744-bbs2-0002" title="AlbersJJ , SleeA , O'BrienKD , RobinsonJG , KashyapML , KwiterovichPOJr , et al. Relationship of apolipoproteins A‐1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM‐HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1575‐9. BaysH , GiezekH , McKenneyJM , O'NeillEA , TershakovecAM . Extended‐release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders2012;10:260‐6. BodenWE , ProbstfieldJL . Extended‐release niacin does not reduce clinical events in patients with established cardiovascular disease whose LDL‐cholesterol is optimally controlled with statin therapy: results from the AIM‐HIGH trial. Circulation2011;124:2370. BodenWE , ProbstfieldJL , AndersonT , ChaitmanBR , Desvignes‐NickensP , KoprowiczK , et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine2011;365:2255‐67. GoldbergRB , BittnerVA , DunbarRL , FlegJL , GrunbergerG , GuytonJR , et al. Effects of extended‐release niacin added to simvastatin/ezetimibe on glucose and insulin values in AIM‐HIGH. American Journal of Medicine2016;129(7):10. GuytonJR , SleeAE , AndersonT , FlegJL , GoldbergRB , KashyapML , et al. Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). Journal of the American College of Cardiology2013;62:1580‐4. Investigators Aim‐High. The role of niacin in raising high‐density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low‐density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM‐HIGH) trial. American Heart Journal2011;161:538‐43. KalilRS , WangJH , DeBoerIH , MathewRO , IxJH , AsifA , et al. Effect of extended‐release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM‐HIGH trial. Kidney International2015;87:1250‐7. LeNA , Farkas‐EppersonM , JinR , TershakovecAM , NeffDR , WolfertR , et al. Changes in lipoprotein‐associated phospholipase A2 with ezetimibe/simvastatin co‐administered with ER niacin in type II hyperlipidemia. Journal of Clinical Lipidology2012;6:253‐4. LyubarovaR , MarcovinaS , FlegJ , NickensP D , TopliceanuA , YaoY , et al. Effects of extended‐release niacin on lipoprotein‐associated phospholipase A2 levels and clinical outcomes in patients with established cardiovascular disease and low baseline levels of HDL‐cholesterol: post hoc analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2080. TeoKK , GoldsteinLB , ChaitmanBR , GrantS , WeintraubWS , AndersonDC , et al. Extended‐release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM‐HIGH) trial. Stroke2013;44:2688‐93. TothP P , JonesS , SleeA , MarcovinaS , FlegJ , BodenW . Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016;1):2130. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW . Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: a post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016;1:2000. TothPP , JonesS , SleeA , FlegJ , MarcovinaS , BodenW , et al. Association between baseline lipoprotein subfractions and outcomes in patients with high triglyceride and low HDL‐cholesterol levels: A post hoc subgroup analysis of the AIM‐HIGH trial. Journal of the American College of Cardiology2016; Vol. 67, issue 13:1236. TothPP , JonesS , SleeA , MarcovinaS , FlegJ , BodenW , et al. Differential treatment effects of extended‐release niacin and placebo on baseline and one‐year lipoprotein subfractions and their relationship to cardiovascular outcomes: Post hoc subset analysis of aim‐high trial patients with high triglyceride and low HDL‐C. Journal of the American College of Cardiology2016; Vol. 67, issue 13:2130. ">AIM‐HIGH 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>341</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0004" title="TaylorAJ , StanekEJ . Flushing and the HDL‐C response to extended‐release niacin. Journal of Clinical Lipidology2008;2:285‐8. TaylorAJ , SullenbergerLE , LeeHJ , LeeJK , GraceKA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double‐blind, placebo‐controlled study of extended‐release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512‐7. ">ARBITER‐2 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD009744-bbs2-0003" title="GuerraA , RanganB V , ColemanA , XuH , KotsiaA , ChristopoulosG , et al. Effect of extended‐release niacin on carotid intima media thickness, reactive hyperemia, and endothelial progenitor cell nobilization: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(12):555‐60. KotsiaAP , RanganBV , ChristopoulosG , ColemanA , RoesleM , CipherD , et al. Effect of extended‐release niacin on saphenous vein graft atherosclerosis: insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE‐SVG) pilot trial. Journal of Invasive Cardiology2015;27(10):E204‐10. ">ALPINE‐SVG 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal and non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD009744-bbs2-0005" title="CapuzziDM , MorganJM , CareyCM , IntenzoC , TulenkoT , KearneyD , et al. Rosuvastatin alone or with extended‐release niacin: a new therapeutic option for patients with combined hyperlipidemia. Preventive Cardiology2004;7:176‐81. CapuzziDM , MorganJM , WeissRJ , ChitraRR , HutchinsonHG , CressmanMD . Beneficial effects of rosuvastatin alone and in combination with extended‐release niacin in patients with a combined hyperlipidemia and low high‐density lipoprotein cholesterol levels. American Journal of Cardiology2003;91:1304‐10. ">Capuzzi 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009744-bbs2-0006" title="NCT00384293 . Carotid IMT (Intima Media Thickening) Study (0524A‐041)(TERMINATED) (ACHIEVE). clinicaltrials.gov/ct2/show/NCT00384293 (accessed 12 January 2016). ">Carotid IMT 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign=""> <p><a href="./references#CD009744-bbs2-0007" title="BergeKG , CannerPL . Coronary Drug Project: experience with niacin. European Journal of Clinical Pharmacology1991;40 Suppl 1:S49‐51. CDP‐Group. The Coronary Drug Project. JAMA1970;214:1303. CDP‐Group. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The Coronary Drug Project Research Group. JAMA1972;220:996‐1008. CannerPL , BergeKG , WengerNK , StamlerJ , FriedmanL , PrineasRJ , et al. Fifteen year mortality in Coronary Drug Project patients: long‐term benefit with niacin. Journal of the American College of Cardiology1986;8:1245‐55. CannerPL , FurbergCD , McGovernME . Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology2006;97:477‐9. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA1975;231:360‐81. ">CDP 1975</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>709</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>633</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>535</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>386</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>839</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>311</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>385</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>167</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0008" title="GoldbergA , AlagonaPJr , CapuzziDM , GuytonJ , MorganJM , RodgersJ , et al. Multiple‐dose efficacy and safety of an extended‐release form of niacin in the management of hyperlipidemia. American Journal of Cardiology2000;85:1100‐5. GoldbergAC . Clinical trial experience with extended‐release niacin (Niaspan): dose‐escalation study. American Journal of Cardiology1998;82:35U‐38U; discussion 39U‐41U. ">Goldberg 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD009744-bbs2-0009" title="BrownWV , FazioS , GuytonJR , DongQ , TomassiniJE , ShahA , et al. 59 relationships between hsCRP reduction and LDL‐C, nonHDL‐C, APOB and HDL‐C in hyperlipidemic patients treated with ezetimibe/simvastatin + extended‐release niacin. Atherosclerosis Supplements2011;12:14. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . 82 combination ezetimibe/simvastatin + extended‐release niacin therapy improves attainment of recommended LDL‐C, Non‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Combination ezetimibe/simvastatin plus extended‐release niacin therapy improves attainment of recommended LDL‐C, NON‐HDL‐C and APOB levels in hyperlipidemic patients. Atherosclerosis Supplements2011;12:20. FazioS , GuytonJR , LinJ , TomassiniJE , ShahA , TershakovecAM . Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, Obesity &amp; Metabolism2010;12:983‐93. FazioS , GuytonJR , PolisAB , AdewaleAJ , TomassiniJE , RyanNW , et al. Long‐term safety and efficacy of triple combination ezetimibe/simvastatin plus extended‐release niacin in patients with hyperlipidemia. American Journal of Cardiology2010;105:487‐94. GuytonJR , BrownBG , FazioS , PolisA , TomassiniJE , TershakovecAM . Lipid‐altering efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in patients with type IIa or type IIb hyperlipidemia. Journal of the American College of Cardiology2008;51:1564‐72. GuytonJR , FazioS , AdewaleAJ , JensenE , TomassiniJE , ShahA , et al. Effect of extended‐release niacin on new‐onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomised controlled trial. Diabetes Care2012;35:857‐60. GuytonJR , FazioS , AdewaleAJ , JensenEH , TomassiniJE , ShahA , et al. New onset diabetes mellitus among patients with type IIa/IIb hyperlipidemia (HL) taking ezetimibe/simvastatin (E/S) +/‐ niacin (N): a randomized trial. Diabetes2009;58:A191. ">Guyton 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New onset diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD009744-bbs2-0010" title="HarikrishnanS , RajeevE , TharakanJA , TitusT , Ajit KumarVK , SivasankaranS , et al. Efficacy and safety of combination of ER niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart Journal2008;60:215‐22. ">Harikrishnan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD009744-bbs2-0011" title='BalasubramanyamA , CorazaI , SmithEO , ScottLW , PatelP , IyerD , et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "Heart Positive," a randomised, controlled trial. Journal of Clinical Endocrinology and Metabolism2011;96:2236‐47. SamsonSL , PownallHJ , ScottLW , BallantyneCM , SmithEO , SekharRV , et al. Heart Positive: design of a randomised controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials2006;27:518‐30. '>Heart positive 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign=""> <p><a href="./references#CD009744-bbs2-0012" title="BallantyneCM , BaysHE , ShahAK , SiskC , DongQ , MaccubbinD . 106 extended release niacin/laropiprant lowers atherogenic lipids across patient subgroups. Atherosclerosis Supplements2011;12:25. BaysHE , MacLeanA , ShahA , McCrary SiskC , DongQ , MaccubbinD . The lipid‐altering effects of extended‐release niacin/laropiprant among different patient subgroups. Journal of Clinical Lipidology2010;4:215. BaysHE , MaccubbinD , MeehanAG , KuznetsovaO , MitchelYB , PaoliniJF . Blood pressure‐lowering effects of extended‐release niacin alone and extended‐release niacin/laropiprant combination: a post hoc analysis of a 24‐week, placebo‐controlled trial in dyslipidemic patients. Clinical Therapy2009;31:115‐22. BaysHE , ShahA , LinJ , McCrary SiskC , PaoliniJF , MaccubbinD . Efficacy and tolerability of extended‐release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Journal of Clinical Lipidology2010;4:515‐21. BostomAG , MacLeanAA , MaccubbinD , TippingD , GizekH , HanlonW . Extended release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes and mild hyperphosphatemia. Arteriosclerosis Thrombosis and Vascular Biology2010;30:E200. Group HPS‐THRIVE Collaborative. HPS2‐THRIVE randomised placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal2013;34:1279‐91. Group HPS‐THRIVE Collaborative, LandrayMJ , HaynesR , HopewellJC , ParishS , AungT , et al. Effects of extended‐release niacin with laropiprant in high‐risk patients. New England Journal of Medicine2014;371:203‐12. HopewellJC , OfferA , ParishS , HaynesR , LiJ , JiangL , et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2‐THRIVE. European Heart Journal2012;33:445. MitchelY . Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1‐5, 2012. Berlin, Germany. Diabetologia2012;55 Suppl 1:S7‐537. MitchelY , BrintonE , TriscariJ , ChenE , Johnson‐LevonasAO , RuckR , et al. Effects of extended‐release niacin/laropiprant (ERN/LRPT) on apolipoprotein (apo) B, LDL‐cholesterol, and non‐HDL‐cholesterol targets in patients with type 2 diabetes. Diabetologia2012;55:S500‐1. ">HPS2‐THRIVE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>694</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>431</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>291</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>411</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>499</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>897</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>732</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New onset diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>376</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>491</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1014</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD009744-bbs2-0013" title="HunninghakeDB , McGovernME , KorenM , BrazgR , MurdockD , WeissS , et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin. Clinical Cardiology2003;26:112‐8. ">Hunninghake 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009744-bbs2-0014" title="LeeJM , RobsonMD , YuLM , ShirodariaCC , CunningtonC , KylintireasI , et al. Effects of high‐dose modified‐release nicotinic acid on atherosclerosis and vascular function: a randomised, placebo‐controlled, magnetic resonance imaging study. Journal of the American College of Cardiology2009;54:1787‐94. ">Lee 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009744-bbs2-0015" title="LeeK , AhnTH , KangWC , HanSH , ChoiIS , ShinEK . The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circulation Journal2011;41:641‐8. ">Lee 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009744-bbs2-0016" title="LinkeA , SonnabendM , FasshauerM , HollriegelR , SchulerG , NiebauerJ , et al. Effects of extended‐release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207‐13. ">Linke 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0017" title="MaccubbinD , BaysHE , OlssonAG , ElinoffV , ElisA , MitchelY , et al. Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice2008;62:1959‐70. ">Maccubbin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New onset diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0018" title="BaysHE , BrintonEA , TriscariJ , ChenE , MaccubbinD , MacLeanA , et al. Extended‐release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients irrespective of baseline glycemic control. Journal of Clinical Lipidology2012;6:270‐1. MacLeanA , McKenneyJM , ScottR , BrintonE , BaysHE , MitchelYB , et al. Efficacy and safety of extended‐release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology2011;18:37‐45 ST. ">MacLean 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD009744-bbs2-0019" title="NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Extended‐release niacin for treatment of dyslipidemia in chronic tetraplegia. Journal of Spinal Cord Medicine2010;33(2):170 ST. NashMS , LewisJE , Dyson‐HudsonTA , SzlachcicY , YeeF , MendezAJ , et al. Safety, tolerance, and efficacy of extended‐release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomised multicentre controlled trial. Archives of Physical Medicine and Rehabilitation2011;92:399‐410. ">Nash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD009744-bbs2-0020" title="GodoyGK , ChahalH , FernandesVR , SibleyC , ChameraE , BluemkeD , et al. Lipid modifying therapy and aortic wall thickness regression by magnetic resonance imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA). Journal of Cardiovascular Magnetic Resonance2010;12:O68. SibleyCT , VavereAL , GottliebI , CoxC , MathesonM , SpoonerA , et al. MRI‐measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart2013;99:1675‐80. ">NIA Plaque 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD009744-bbs2-0021" title="CaruzzoC , LiboniW , BonzanoA , BobbioM , BongioanniS , CaruzzoE , et al. Effect of lipid‐lowering treatment on progression of atherosclerotic lesions‐‐a duplex ultrasonographic investigation. Angiology1995;46:269‐80. ">PAST 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinuation of treatment due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD009744-bbs2-0022" title="SangZC , WangF , ZhouQ , LiYH , LiYG , WangHP , et al. Combined use of extended‐release niacin and atorvastatin: safety and effects on lipid modification. Chinese Medicine Journal2009;122:1615‐20. ">Sang 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Revascularisation procedures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD009744-bbs2-0023" title="SchnaperHW , SchochHK , DetreK . Veterans administration cardiology drug‐lipid study ‐ a progress report. Circulation1969;40:I180‐&amp;. SchochHK . The US veterans administration cardiology drug‐lipid study: an interim report. Advances in Experimental Medicine and Biology1968:405‐20. ">Schoch 1968</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatal or non‐fatal myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number randomised, complete, missing, and events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/full#CD009744-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009744-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Niacin versus control, maximum follow‐up, available case analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.97, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall mortality, sensitivity analysis with stratification by risk of bias trials only <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.97, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.00, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.91, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Non‐cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Fatal or non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Fatal and non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Revascularisation procedures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Flushing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.69 [4.14, 14.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.26 [2.68, 10.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Rash <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [1.94, 5.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.86, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Gastrointestinal symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.37, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Discontinuation of treatment due to side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.70, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 New onset diabetes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.16, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Niacin versus control, maximum follow‐up, available case analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009744.pub2/references#CD009744-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009744.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009744-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009744-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009744-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009744-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD009744-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009744-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009744-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009744\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009744\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009744\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009744\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009744\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009744.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009744.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009744.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009744.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009744.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716944935"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009744.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716944939"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009744.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dabddbf6bf3f1',t:'MTc0MDcxNjk0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 